What is a multidisciplinary tumor board and should my Multiple Myeloma case be presented

Understanding Multidisciplinary Tumor Boards for Multiple Myeloma

What Is a Multidisciplinary Tumor Board?

A multidisciplinary tumor board (often called a "tumor board" or "molecular tumor board") is an interdisciplinary team of cancer experts who meet together to review and discuss individual patient cases. These specialists typically include:

• Medical oncologists (cancer drug specialists)
• Pathologists (experts who examine tissue samples)
• Radiologists (imaging specialists)
• Surgeons (if surgical options are relevant)
• Other specialists depending on your specific situation

How it works: Your [ID removed] test results, imaging scans, and pathology reports are presented to this team. They discuss your case together and provide recommendations about the best treatment approach for YOUR specific situation.

Why Tumor Boards Matter for Multiple Myeloma

According to the NCCN Guidelines for Patients: Multiple Myeloma, having your case reviewed by experienced specialists is important because:

• Multiple myeloma has many treatment options. As the guidelines note, "there are many different kinds of treatment for multiple myeloma," and the right choice depends on your individual circumstances
• Treatment decisions made early affect later options. The guidelines specifically state: "Treatment decisions made by a non-myeloma specialist can seriously affect later treatment decisions"
• Myeloma is complex. Your specific genetic markers (like FISH results showing chromosome abnormalities), your fitness level, kidney function, and whether you're a candidate for a hematopoietic cell transplant all influence which treatment is best

Should Your Case Be Presented?

Yes—strongly consider requesting a tumor board review, especially if:

✅ You're newly diagnosed and haven't started treatment yet
✅ Your myeloma is relapsing or becoming resistant to current therapy
✅ You have complex genetic features (high-risk chromosomal abnormalities like del(17p), t(4;14), or t(14;16))
✅ You're considering a hematopoietic cell transplant (bone marrow/stem cell transplant)
✅ You want a second opinion before starting treatment
✅ Your disease isn't responding as expected to your current treatment

Important Context: Molecular Tumor Boards

The NCCN guidelines reference molecular tumor boards—specialized boards that review genetic testing results (like your FISH analysis, chromosome deletions, and other biomarkers) to help match you with the most targeted treatment options.

One important limitation to know: Research shows that when the same molecular test results are sent to different tumor boards, the treatment recommendations only agree about 44-63% of the time. This means tumor boards are helpful, but they're not perfect—which is why your input and questions matter, and why getting a second opinion is always reasonable.

Questions to Ask Your Care Team

1. "Can my case be presented to a multidisciplinary tumor board?" (Many major cancer centers do this routinely)
2. "Will a molecular tumor board review my genetic test results to help guide treatment selection?"
3. "Are you a myeloma specialist, or would you recommend I see one?" (The NCCN guidelines emphasize that myeloma specialists have more experience with this disease)
4. "If I want a second opinion from another myeloma specialist, how can I arrange that?"
5. "What are the pros and cons of the specific treatment combination you're recommending for me?"

Getting a Second Opinion

The NCCN Guidelines for Patients emphasize: "It's normal to want to start treatment as soon as possible. Still, there's usually enough time to have another cancer care provider review your test results and suggest a treatment plan. This is called getting a second opinion, and it's a normal part of cancer care."

Most people with myeloma have time for a second opinion—especially from a myeloma specialist—before starting treatment.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.